Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of the herpes group.

Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.

Abstract: The present invention provides a compound selected from:N-[4-(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-2-flurobenzoyl] -(L)-glutamic acid,N-[4-( 3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-flurobenzoyl ]-(L)-glutamic acid,N-[4 -(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-methylbenzoyl ]-(L)-glutamic acid,N-[4-( 2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-(methoxy)benzoy l](L)-glutamic acid andN-[4-(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-2-chlorobenzoyl ](L)-glutamic acid,or a salt thereof, methods for the preparation of the compounds, intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of tumors.

Abstract: The present invention provides a compound of formula (I): ##STR1## wherein Y is oxygen; R.sup.2 and R.sup.3 are the same or different and are hydrogen or C.sub.1-4 alkyl; R.sup.4 is NR.sup.11 R.sup.12 ; R.sup.11, R.sup.12, R.sup.5 and R.sup.6 are the same or different and are hydrogen, C.sub.1-4 alkyl or C.sub.1-12 acyl; R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are the same or different and are hydrogen, halo, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and n is 2, 3, 4 or 5; m is 0 or an integer from 1 to 5; or a salt thereof, methods for the preparation of the compounds of the formula (I), intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of neoplastic growth.

Abstract: The present invention provides a compound of formula (I): ##STR1## wherein Y is sulfur; R.sup.2 and R.sup.3 are the same or different and are hydrogen or C.sub.1-4 alkyl; R.sup.4 is NR.sup.11 R.sup.12 ; R.sup.11, R.sup.12, R.sup.5 and R.sup.6 are the same or different and are hydrogen, C.sub.1-4 alkyl or C.sub.1-12 acyl; R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are the same or different and are hydrogen, halo, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and n is 2, 3, 4 or 5; m is 0 or an integer from 1 to 5; or a salt thereof, methods for the preparation of the compounds of the formula (I), intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of neoplastic growth.

Abstract: This invention provides the pterin compounds of formula (I) and use in human and veterinary medicine. ##STR1## wherein R represents lower alkyl groups (straight or branched) of 1-8 carbons (for this formula and all other formulas herein) including all stereo isomers thereof or a pharmaceutically acceptable salt thereof.

Abstract: The compounds of formula (I) ##STR1## wherein R.sup.1 is hydrogen, lower alkyl of 1-4 carbons, lower alkenyl of 2-4 carbons, --B--X--R.sup.5).sub.n, or --B--Z--B--X--R.sup.5 --.sub.n ; n=0 when X is halogen or n=1 when X is --O--, --NR.sup.6 -- (where R.sup.6 is hydrogen or lower alkyl of 1-4 carbons) or --S(O)q-- (where q=0 to 2); B is lower alkanyl (straight or branched) of 1-5 carbons; R.sup.5 is hydrogen, aralkyl of 7 to 12 carbons or alkyl of 1-10 carbons; Z is --O--, NR.sup.6 --, or --S(O)q--; R.sup.2 is hydrogen or lower alkyl of 1-4 carbons or lower alkenyl of 2-4 carbons or either R.sup.1 and R.sup.2 together with the carbon atom in the pteridine ring structures to which they are attached, form a spirocycloalkyl ring system having 3 to 7 carbon atoms; R.sup.3 and R.sup.4 are hydrogen or methyl; R.sup.2 and R.sup.3, together with the carbon atoms in the pteridine ring structure to which they are attached, form a cycloalkyl ring system having 5 to 7 carbon atoms; provided that at least one of R.sup.

Abstract: This invention provides the intermediates of formula II-A below, useful to make the pterin compounds of formula I below. The pterin compounds are used in human and veterinary medicine. ##STR1## wherein R represents a lower alkyl of 1 to 8 carbons.

Abstract: 6'-Acylaminopenicillanoyloxymethyl esters of penicillanic acid 1,1-dioxide are useful as antibacterial agents. The 6'-aminopenicillanoyloxymethyl ester, halomethyl esters, alkylsulfonyloxymethyl esters and arylsulfonyloxymethyl esters of penicillanic acid 1,1-dioxide are all useful intermediates for the aforesaid antibacterial agents.

Abstract: 6'-Acylaminopenicillanoyloxymethyl esters of penicillanic acid 1,1-dioxide and useful as antibacterial agents. The 6'-aminopenicillanoyloxymethyl ester, halomethyl esters, alkylsulfonyloxymethyl esters and arylsulfonyloxymethyl esters of penicillanic acid 1,1-dioxide are all useful intermediates for the aforesaid antibacterial agents.

Abstract: 6'-Acylaminopenicillanoyloxymethyl esters of penicillanic acid 1,1-dioxide are useful as antibacterial agents. The 6'-aminopenicillanoyloxymethyl ester, halomethyl esters, alkylsulfonyloxymethyl esters and arylsulfonyloxymethyl esters of penicillanic acid 1,1-dioxide are all useful intermediates for the aforesaid antibacterial agents.

Abstract: Penicillanoyloxymethyl penicillanate 1,1,1',1'-tetraoxide; a method of treating a bacterial infection in a mammalian subject using penicillanoyloxymethyl penicillanate 1,1,1',1'-tetraoxide and a beta-lactam antibiotic; and pharmaceutical compositions comprising a suspension of penicillanoyloxymethyl penicillanate 1,1,1',1'-tetraoxide in water.

Abstract: 6'-Acylaminopenicillanoyloxymethyl esters of penicillanic acid 1,1-dioxide are useful as antibacterial agents. The 6'-aminopenicillanoyloxymethyl ester, halomethyl esters, alkylsulfonyloxymethyl esters and arylsulfonyloxymethyl esters of penicillanic acid 1,1-dioxide are all useful intermediates for the aforesaid antibacterial agents.

Abstract: Azidomethylarylacetic acids and derivatives thereof are prepared by oxidative rearrangement of the corresponding azidomethylarylmethyl ketones effected by thallium (III) nitrate in the presence of methanol or ethanol and certain acids to obtain methyl or ethyl esters of the desired azidomethylarylacetate. When desired, the acids are obtained by hydrolysis of said esters. The azidomethylarylacetic acids are valuable intermediates in the preparation of aminomethylarylmethylpenicillins and aminomethylarylmethylcephalosporins.